{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:24Z","timestamp":1791357384617,"version":"4.3.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T00:00:00Z","timestamp":1418688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100005632","name":"Forest Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003358","name":"Gedeon Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017301","name":"Forest Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jad.2014.11.018","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T16:36:30Z","timestamp":1416846990000},"page":"296-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"special_numbering":"C","title":["Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial"],"prefix":"10.1016","volume":"174","author":[{"given":"Gary S.","family":"Sachs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Laszlovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Durgam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2014.11.018_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.jad.2014.11.018_bib2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.018_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1146\/annurev.pharmtox.011008.145634","article-title":"Akt\/GSK3 signaling in the action of psychotropic drugs","volume":"49","author":"Beaulieu","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jad.2014.11.018_bib4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1523\/JNEUROSCI.5074-06.2007","article-title":"Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo","volume":"27","author":"Beaulieu","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jad.2014.11.018_bib5","unstructured":"Calabrese, J.R., Keck, P.E., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Nemeth, G., Durgam, S. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry (in press)"},{"key":"10.1016\/j.jad.2014.11.018_bib6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s12272-010-1005-8","article-title":"Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors","volume":"33","author":"Cho","year":"2010","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jad.2014.11.018_bib7","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","author":"Durgam","year":"2014","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2014.11.018_bib8","article-title":"Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor \u00df-arrestin interactions","author":"Gao","year":"2014","journal-title":"Pharma Res Per."},{"key":"10.1016\/j.jad.2014.11.018_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","article-title":"The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO","volume":"66","author":"Graff-Guerrero","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.018_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-642-25758-2_7","article-title":"The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions","author":"Gross","year":"2012","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.jad.2014.11.018_bib11","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"218","article-title":"The abnormal movement scale","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2014.11.018_bib12","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"218","article-title":"The clinician global severity and impression scales","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2014.11.018_bib13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881108094349","article-title":"Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors\u2014a new analysis of data from the archives and implications for improved antimanic treatments","volume":"23","author":"Harrison-Read","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.11.018_bib14","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/sim.4780141706","article-title":"Combining 2\u00d72 tables that contain structural zeros","volume":"14","author":"Johnson","year":"1995","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2014.11.018_bib15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","article-title":"Dopamine D3 receptor antagonists as therapeutic agents","volume":"10","author":"Joyce","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jad.2014.11.018_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2014.11.018_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/biomet\/90.1.53","article-title":"Pattern-mixture models with proper time dependence","volume":"90","author":"Kenward","year":"2003","journal-title":"Biometrika"},{"issue":"suppl 1","key":"10.1016\/j.jad.2014.11.018_bib18","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0920-9964(12)70588-1","article-title":"Cariprazine, a D3\/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics","volume":"136","author":"Kiss","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2014.11.018_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2014.11.018_bib20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2014.11.018_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jad.2014.11.018_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2013.07.022","article-title":"Dopamine D3 receptor as a new pharmacological target for the treatment of depression","volume":"719","author":"Leggio","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jad.2014.11.018_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"Leung","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2014.11.018_bib24","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/npp.2010.50","article-title":"The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective exvivo but not invitro","volume":"35","author":"McCormick","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2014.11.018_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2307\/2530927","article-title":"Exact significance testing to establish treatment equivalence with ordered categorical data","volume":"40","author":"Mehta","year":"1984","journal-title":"Biometrics"},{"key":"10.1016\/j.jad.2014.11.018_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","article-title":"Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO","volume":"131","author":"Mizrahi","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2014.11.018_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.018_bib28","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.018_bib29","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4088\/JCP.10ac06470yel","article-title":"New antipsychotic drugs: how do their receptor-binding profiles compare?","volume":"71","author":"Richelson","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.018_bib30","doi-asserted-by":"crossref","first-page":"704","DOI":"10.4088\/JCP.10m06523","article-title":"The pharmacologic treatment of bipolar disorder","volume":"72","author":"Sachs","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"suppl 6","key":"10.1016\/j.jad.2014.11.018_bib31","first-page":"S18","article-title":"Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals?","volume":"64","author":"Sachs","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.018_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"suppl 3","key":"10.1016\/j.jad.2014.11.018_bib33","first-page":"S9","article-title":"Desribing an Atypical antipsychotic: receptor binding and its role in pathophysiology","volume":"5","author":"Stahl","year":"2003","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.018_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1461145709991246","article-title":"Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis","volume":"13","author":"Tamayo","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2014.11.018_bib35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jad.2014.11.018_bib36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/npp.2010.192","article-title":"Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials","volume":"36","author":"Yildiz","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2014.11.018_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032714007289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032714007289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:15:16Z","timestamp":1759022116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032714007289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":37,"alternative-id":["S0165032714007289"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2014.11.018","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2014.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}